Founded in 2010, BeyondSpring is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies, centered on its investigational lead asset Plinabulin. The Florham Park company is advancing Plinabulin as a GEF-H1 agonist that promotes dendritic-cell maturation and may help re-sensitize tumors after checkpoint-inhibitor treatment while reducing chemotherapy-induced neutropenia. Its development program has treated more than 700 cancer patients and includes the confirmatory DUBLIN-4 Phase 3 program in non-small-cell lung cancer.
Zetagen TherapeuticsFounded in 2015, Zetagen Therapeutics is a private, clinical-stage biopharmaceutical company built around a patient-centered approach to cancer research. From its Colleen Connor Cancer Research Lab, the company develops local treatments for people with metastatic cancer affecting bone, including the investigational therapy ZetaMet, which is designed to address tumors while supporting bone repair.SYRACUSE, NY
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA
Iovance Biotherapeutics, IncIovance Biotherapeutics develops and manufactures personalized tumor-infiltrating lymphocyte (TIL) cell therapies for people with cancer. Its 136,000-square-foot Iovance Cell Therapy Center in Philadelphia makes TIL therapy using proprietary processes, including a 22-day Gen 2 process; the company also markets Amtagvi and Proleukin.PHILADELPHIA, PA
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV